
Cardiff Oncology CRDF
$ 2.4
0.23%
Quarterly report 2025-Q3
added 11-06-2025
Cardiff Oncology Cost of Revenue 2011-2025 | CRDF
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Cardiff Oncology
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 597 K | 1.81 M | 1.73 M | 629 K | 15.4 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.81 M | 15.4 K | 957 K |
Quarterly Cost of Revenue Cardiff Oncology
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 26.7 K | 204 K | 366 K | - | 473 K | 338 K | 616 K | - | 425 K | 409 K | 309 K | - | 174 K | 80 K | 176 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 616 K | 26.7 K | 300 K |
Cost of Revenue of other stocks in the Biotechnology industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
32.2 M | - | 2.43 % | $ 254 M | ||
|
Aclaris Therapeutics
ACRS
|
2.79 M | $ 3.2 | -1.69 % | $ 247 M | ||
|
Aptevo Therapeutics
APVO
|
19.9 M | $ 1.07 | -5.75 % | $ 295 K | ||
|
Ascendis Pharma A/S
ASND
|
3.52 M | $ 213.33 | -3.22 % | $ 5 B | ||
|
Midatech Pharma plc
MTP
|
926 K | - | -18.52 % | $ 27.3 M | ||
|
BioVie
BIVI
|
312 K | $ 1.42 | -1.85 % | $ 2.1 M | ||
|
Acasti Pharma
ACST
|
76 K | - | 4.01 % | $ 150 M | ||
|
BioNTech SE
BNTX
|
2.91 B | $ 93.93 | -0.93 % | $ 27.2 B | ||
|
Albireo Pharma
ALBO
|
1.36 M | - | -0.23 % | $ 916 M | ||
|
Ampio Pharmaceuticals
AMPE
|
369 K | - | -11.43 % | $ 502 K | ||
|
Amphastar Pharmaceuticals
AMPH
|
358 M | $ 26.45 | 4.67 % | $ 1.28 B | ||
|
Anika Therapeutics
ANIK
|
63.6 M | $ 9.6 | 0.37 % | $ 141 M | ||
|
Catalyst Biosciences
CBIO
|
4.64 M | $ 12.98 | -7.91 % | $ 854 M | ||
|
Axon Enterprise
AXON
|
841 M | $ 548.58 | -2.78 % | $ 41.6 B | ||
|
Ayala Pharmaceuticals
AYLA
|
602 K | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
20.6 M | $ 2.37 | 2.83 % | $ 14.9 M | ||
|
AstraZeneca PLC
AZN
|
12.4 B | $ 91.59 | 1.95 % | $ 96.9 B | ||
|
Celldex Therapeutics
CLDX
|
200 K | $ 27.09 | -1.53 % | $ 1.74 M | ||
|
Acorda Therapeutics
ACOR
|
15.3 M | - | -24.86 % | $ 820 K | ||
|
BeiGene, Ltd.
BGNE
|
70.7 M | - | 0.49 % | $ 251 B | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
91.7 M | $ 11.33 | -1.78 % | $ 733 M | ||
|
Biogen
BIIB
|
2.31 B | $ 175.2 | 0.63 % | $ 25.5 B | ||
|
Corcept Therapeutics Incorporated
CORT
|
10.9 M | $ 87.67 | -0.36 % | $ 9.05 B | ||
|
ADiTx Therapeutics
ADTX
|
627 K | $ 1.43 | -36.18 % | $ 18.8 K | ||
|
Bellicum Pharmaceuticals
BLCM
|
436 K | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
24.8 M | - | -7.31 % | $ 87 M | ||
|
Advaxis
ADXS
|
13 K | - | -9.65 % | $ 45.9 M | ||
|
Catalyst Pharmaceuticals
CPRX
|
68.8 M | $ 24.29 | 2.84 % | $ 2.88 B |